Mammoth Biosciences Overview
- Founded
- 2017
- Status
- Private
- Employees
- 145
- Latest Deal Type
- Later Stage VC
- Investors
- 26
Mammoth Biosciences General Information
Description
Developer of a CRISPR-based detection platform designed to democratize disease detection. The company's platform provides an easy and affordable point-of-need test that allows rapid and simultaneous detection of multiple conditions, enabling healthcare providers, researchers, and biotech professionals to have access to an efficient platform for molecular diagnostics.
Contact Information
- 1000 Marina Boulevard
- Suite 600
- Brisbane, CA 94005
- United States
Mammoth Biosciences Timeline
Mammoth Biosciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC | 00000 | Completed | Generating Revenue | |||
6. Later Stage VC (Series D) | 09-Sep-2021 | 00000 | 00000 | 00.000 | Completed | Generating Revenue |
5. Later Stage VC (Series C) | 19-May-2020 | 0000 | 00000 | 00000 | Completed | Generating Revenue |
4. Early Stage VC (Series B) | 30-Jan-2020 | 0000 | 000.00 | 00000 | Completed | Generating Revenue |
3. Early Stage VC (Series A) | 30-Jul-2018 | 0000 | 000.00 | 0000 | Completed | Generating Revenue |
2. Accelerator/Incubator | 24-Jan-2018 | $120K | Completed | Generating Revenue | ||
1. Accelerator/Incubator | 15-May-2017 | $120K | $120K | 0000 | Completed | Startup |
Mammoth Biosciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series D-1 | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 0.000 |
Series D | 00,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 0.00 |
Series C-1 | 000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Series C | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B-1 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Series B | 13,631,447 | $0.000100 | 8% | $2.7 | $2.7 | 1x | $2.7 | 17.06% |
Series A | 18,051,205 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 22.59% |
Mammoth Biosciences Comparisons
Industry
00000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialMammoth Biosciences Competitors (17)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Sherlock Biosciences | Venture Capital-Backed | Boston, MA | 00 | 00000 | 00000000000 | 00000 |
00000000 00000000 | Formerly VC-backed | San Diego, CA | 00 | 000.00 | 00000000 | |
0000 00000000 | Venture Capital-Backed | San Diego, CA | 000 | 00000 | 000000 - 000 | 00000 |
00000000 | Venture Capital-Backed | Pleasanton, CA | 00 | 0000 | 000000000 - | 0000 |
0000000000 0000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00000 | 00000000000 |
Mammoth Biosciences Patents
Mammoth Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210009974-A1 | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection | Granted | 04-Jan-2019 | 0000000000 | |
US-11174470-B2 | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection | Active | 04-Jan-2019 | 0000000000 | 000 |
US-20210078002-A1 | Programmable nuclease compositions and methods of use thereof | Pending | 01-Aug-2018 | 0000000000 | |
US-20210102242-A1 | Programmable nuclease compositions and methods of use thereof | Pending | 01-Aug-2018 | 0000000000 | |
EP-3830301-A1 | Programmable nuclease compositions and methods of use thereof | Pending | 01-Aug-2018 | C12Q1/6816 |
Mammoth Biosciences Executive Team (9)
Mammoth Biosciences Board Members (6)
Name | Representing | Role | Since |
---|---|---|---|
Dean Minor MD | Mammoth Biosciences | Board Member | 000 0000 |
Jeff Huber Ph.D | Mammoth Biosciences | Board Member | 000 0000 |
Jennifer Doudna Ph.D | Mammoth Biosciences | Co-Founder & Chair of Scientific Advisory Board | 000 0000 |
Maneesh Jain Ph.D | Self | Board Member | 000 0000 |
Ursheet Parikh | Mayfield (Private Equity) | Board Member | 000 0000 |
Mammoth Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMammoth Biosciences Investors (26)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Senator Investment Group | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Sixth Street Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
Amazon.com | Corporation | Minority | 000 0000 | 000000 0 | |
Foresite Capital Management | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
Redmile Group | Hedge Fund | Minority | 000 0000 | 000000 0 |